Save the Date!

Wednesday, May 4, 2022 is MACEP's Annual Meeting

Alexion



CONTACT INFORMATION

Jennifer Chase
Jennifer.chase@alexion.com
617-877-8206
 
Alexion Pharmaceuticals
121 Seaport Blvd
Boston, MA 02210


COMPANY INFORMATION

Intended for US audiences only
 
Alexion is a global biopharmaceutical company with the mission of helping the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
US/POR-ADX/1473


PRODUCT INFORMATION


ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
 
Treatment with ANDEXXA has been associated with serious and life threatening adverse events, including:
•            Arterial and venous thromboembolic events
•            Ischemic events, including myocardial infarction and ischemic stroke
•            Cardiac arrest
•            Sudden deaths
 
Please see full Prescribing Information including Boxed Warning on thromboembolic risks, ischemic risks, cardiac arrest, and sudden death

Mechanistic Rationale for Targeted Reversal of Factor Xa Inhibition